Background: With an annual volume of total knee arthroplasties (TKAs) in the United States projected to exceed 1.5 million by 2050, optimizing perioperative pain control and facilitating early discharge remain clinical priorities. This study evaluated the effectiveness of liposomal bupivacaine (LB) vs conventional bupivacaine/ropivacaine in opioid-naïve patients undergoing primary TKA, comparing/contrasting: (1) pain score improvements, (2) opioid usages, (3) functional recoveries, and (4) hospital lengths of stay. Methods: < .05. Results: = .007). Conclusions: Use of LB is associated with improved pain control, reduced opioid use, and shorter lengths of stay following TKA. This study highlights LB's utility in facilitating early mobilization and advancing perioperative care.
Ng et al. (Fri,) studied this question.